S. 845 · 118th Congress (2023–2025)
Short on Competition Act
This bill requires the Food and Drug Administration (FDA) to provide temporary authorization to import certain prescription drugs facing shortages or in a marginally competitive drug market.
Specifically, the FDA shall authorize importation of an eligible drug that is lifesaving, life-sustaining, or intended to treat or prevent a debilitating condition. To be eligible, a drug must (1) be facing a shortage, (2) require a prescription, (3) have received market authorization in certain foreign countries, and (4) have the same active ingredient as the drug for which there is a shortage in the United States. The drug's manufacturer must also seek FDA approval for the drug as a generic drug.
The import authorization shall be for three years or until the shortage no longer applies, whichever occurs first. Importation shall begin within 60 days of the FDA receiving an application that meets all of the applicable requirements. The FDA may deny importation of a drug for reasons related to safety or effectiveness.
Drugs in marginally competitive markets must be treated as being in a shortage for the purposes of this bill and for the purposes of expedited inspections and review. A drug is in a marginally competitive market if (1) there are fewer than five holders of approved applications for commercially available brand-name or generic versions of the drug, (2) the drug has been approved for at least 10 years, and (3) the patents on the drug's active ingredients have expired.
Show official title
A bill to allow for expedited approval of generic prescription drugs and temporary importation of prescription drugs in the case of marginally competitive drug markets and drug shortages.
Expired in Senate committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to committee
This bill’s path
This is S. 845’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed Senate
Passed House
Sent to President
Signed into law
Expired
- Sponsor
- Sen. Amy Klobuchar (D-MN)
- Cosponsors
3 cosponsors
3 original · 0 later
- Sen. Richard J. Durbin (D-IL)· Original · Mar 16, 2023
- Sen. Chuck Grassley (R-IA)· Original · Mar 16, 2023
- Sen. Mike Lee (R-UT)· Original · Mar 16, 2023
- Policy area
- Health
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in Senate
Document: Introduced in Senate
Sources
- Congress.gov action
- Library of Congress
- Latest
Referred to committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sources
- Congress.gov action
- Senate
Expired
Introduced → Referred to Senate Health, Education, Labor, and Pensions → No further action before the 118th Congress ended.
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in Senate |
Titles (2)
Short on Competition Act
Display title, Short title · Introduced in Senate
A bill to allow for expedited approval of generic prescription drugs and temporary importation of prescription drugs in the case of marginally competitive drug markets and drug shortages.
Official title · Introduced in Senate